Neurocrine Bioscienc (NBIX)

Citizens reit'd $CRNX Mkt OP-$90 and said, " $CRNX presented new long-term safety and efficacy data from its open-label extension (OLE) trial of PATHFNDR-1, showing paltusotine maintained IGF-1 levels comparable to prior injected SRL therapy for up to 60 weeks. $NBIX Citizens went on to say:

WATCHLIST JUL 15 2025 $NBIX Neurocrine Biosciences CRENESSITY Shows Clinically Meaningful Weight Loss And Insulin Resistance Improvement In Adults And Children With CAH In Phase 3 Trials, Presented At ENDO 2025 $DNB Chorus Intelligence And Dun & Bradstreet Partner To Empower Law Enforcement And Financial Services With Real-Time Business Intelligence $CSTM Constellium Advances Smart Aluminum Auto Structures With ARENA2036, Unveils Modular Sill Concept And FlexCAR Project Completion $ITT ITT's Svanehøj Wins Contract To Supply Deepwell Pumps For Next-Gen Ultra Large Ethane Carriers, Marking First Entry Into ULEC Segment $SPIR Spire Global Bags $1.2M, Two-Month Task Order Extension Modification From NASA To Continue Participation In Commercial Satellite Data Acquisition Program

Goldman Sachs, on 7/10,🏁 $NBIX Buy-$182. $CRNX $TAK $BMY Goldman Sachs said in its initiation report:

Piper Sandler reiterated $PRAX Overweight-$270 and Provided its Takeaways From Their Well-Attended NYC Investor Dinner, Ahead of Ph2 RADIANT $NBIX $BHVN $XENE AQST $BIIB DNLI JAZZ UCBJF Piper Sandler said in it research report:

Goldman Sachs has updated their rating for Neurocrine Biosciences ( $NBIX ) to Buy with a price target of 182.

$NBIX UBS Maintains Buy on Neurocrine Biosciences, Raises Price Target to $174

UBS⬆️ $NBIX PT to $174 from $152, reiterated Buy and said, "Lot less polarized vs 4Q24 and 1Q25 set-up: we expect outperformance at 2Q" $CRNX $TAK UBS added, "We continue to see steady upside on the stock for remainder of 2025. For the stock to break from the recent range-bound action, we believe consistently strong uptake on Crenessity is key. Based on our incomings, we believe the stock is lot less polarized heading into the 2Q25 print, as opposed to 4Q24 (Crenessity elevated expectations) and 1Q25 (Ingrezza bear case). We are raising our PT to $174 (from $152) based on 5.25x EV/'30E sales (prior 4.5x), supported by a DCF; we increase our multiple to reflect an increasing growth narrative with early bullish indicators for Crenessity launch. Crenessity physician checks indicate 400+ new patient starts realistic in 2Q" UBS went on to say:

Citizens reiterated $CRNX Market Outperform-$90. $NBIX $CORT $IMVT $BBIO ARGX VRDN AMGN TRML RGLS - NVS VRTX Citizens said in its note: "Crinetics ( $CRNX, MO, $90 PT) will present Phase 2 TouCAHn data for atumelnant in congenital adrenal hyperplasia (CAH) during the oral session "All About Congenital Adrenal Hyperplasia and Adrenal Insufficiency" on Saturday, July 12. While the abstract remains embargoed, previously released data show the once-daily oral ACTH antagonist induces rapid and sustained reductions of androstenedione and 17- hydroxyprogesterone over 12 weeks, with most patients normalizing A4 within two weeks (our coverage here). Importantly, atumelnant had greater A4 reductions than Neurocrine's ( $NBIX, NC) approved drug Crenessity, which could translate to greater glucocorticoid (GC) reductions (the regulatory endpoint). $CRNX will also present two posters on reductions in adrenal volume and 11-oxygenated androgens in the Phase 2 trial. Citizens goes on to say:

H.C. Wainwright reiterated $CRNX Buy-$81 and said, "One of the pillars of our investment thesis in Crinetics has been the company's ability to discover new drugs." $NBIX H.C. Wainwright went on to say:

$NBIX Neurocrine Biosciences stock, watch for an upside gap breakout at https://stockconsultant.com/?NBIX

Neurocrine's new Phase 4 data shows INGREZZA significantly improves quality of life in older adults with TD. Presented at AANP today, this builds on their robust clinical evidence. $NBIX continues to strengthen its position in movement disorders. Bullish as real-world impact meets aging population needs. https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-new-data-showing-significant-patient-reported-improvements-in-health-related-quality-of-life-with-ingrezza-valbenazine-capsules-in-older-adults-with-tardive-dyskinesia-302485804.html

$NBIX Neurocrine presents new data on patient-reported improvements with INGREZZA Neurocrine Biosciences announced the presentation of new analyses from a Phase 4 randomized withdrawal study demonstrating significant patient-reported improvements in health-related quality of life and functional measures among adults aged 65 years and older with tardive dyskinesia who received continued treatment with INGREZZA capsules. Findings will be presented at the 2025 American Association of Nurse Practitioners National Conference in San Diego. These post-hoc analyses of older adults expand on recently announced Phase 4 study results, which demonstrated that continued treatment with INGREZZA improved functional status and quality of life measures across the general patient population. Patients who received continued treatment with INGREZZA reported significant improvements in health-related quality of life and functional status, compared with those randomized to placebo. Two clinically validated scales were used to assess patient-reported outcomes, providing a comprehensive and scientifically robust measure of health status: The EuroQol 5-Dimension 5-Level assessment tool, which measures health-related quality of life across five dimensions of health status; The Sheehan Disability Scale, which measures patient-reported functional impairment in work/school, social life and family/home life impairment.

RBC Capital⬆️ $XENE PT to $57 from $55, reit'd its OP and said, "Analysis Shows Strong Historical Ph.Il to Ph.III Translatability For Epilepsy Drugs" $BHVN $NBIX $JAZZ RBC added, "Our analysis of historical focal onset efficacy studies shows high translatability between ph.Il and ph.Ill on seizure reductions and responder rate, suggesting a good likelihood azetukalner's ph.Ill data early next year should mostly recapitulate their promising ph.Il data. Even under conservative assumptions, azetukalner's efficacy, novel Kv7 MOA, rapid onset, and potential mood benefits, in a space dominated by polypharmacy, should be highly competitive and give the drug an impt, $1.2B (RBCe) future role. Therapeutic window remains key, though having two tested dose options should help real-world pt management. Shares appear to underappreciate azetukalner's opportunity; increasing tgt to $57 on higher PoS and see favorable stock setup into ph.Ill data."

$NBIX Buy &Hold. For more information visit my site. Investment Scoreboard:

$NBIX = BEAUTIFUL 😍 3 month chart! WOW 📈📈

5 Biotech Stocks with great growth Potential 🧬 • $VRTX – Gene therapy approvals gaining traction • $CRSP – Advancing CRISPR pipeline toward late stage • $NBIX – Neurology assets showing strong trial results • $REGN – Diversified biologics revenue + AI in drug discovery • $AKRO – NASH pipeline could be a long-term win Follow us for more daily alerts 🔱

RBC Capital updates rating for Neurocrine Biosciences ( $NBIX ) to Outperform, target set at 145.

$NBIX From share buybacks to Phase 3 trials, Neurocrine Biosciences is executing on all fronts. See why analysts are bullish on NBIX stock. https://biotechhealthx.com/biotech-news/neurocrine/

$NBIX the 3 month NBIX chart is showing a very Bullish phase has begun 📈

$NBIX my guess would be NVS

$NBIX set up for a buy out.

$NBIX buying below 100 really was a no brainer here